Working Paper of Public Health Volume 2012 - Azienda Ospedaliera ...

More documents

Recommendations

Info

Azienda Ospedaliera Nazionale“SS. Antonio e Biagio e Cesare Arrigo”Working Paper of Public Healthnr. 12/2012[121] M.T. Petrucci, C. Gallucci, A. Agrillo, M.C. Mustazza, R. Foà, “Role of ozone therapyin the treatment of osteonecrosis of the jaws in multiple myeloma patients,” Haematologic,vol. 92, no. 9, pp. 1289-1290, 2007.[122] A. Agrillo, C. Ungari, F. Filiaci, P. Priore, G. Iannetti, “Ozone therapy in the treatmentof avascular bisphosphonate-related jaw osteonecrosis,” J Craniofac Surg., vol. 18, no. 5, pp.1071-1075, 2007[123] C.I. Ripamonti, E. Cislaghi, L. Mariani, M. Maniezzo, “Efficacy and safety of medicalozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of thejaw in patients with bone metastases treated with bisphosphonates: Preliminary results of aphase I-II study,” Oral Oncol., vol 47, no. 3, pp. 185-190, 2011.[124] P.Vescovi, “Osteonecrosi mascellari e bifosfonati: prevenzione, diagnosi e terapia,”Stamperia, Parma, Italia, 2007.[125] P.Vescovi, “Osteonecrosi dei mascellari e bifosfonati” Tecniche Nuove, Milano, Italia,2008.[126] R.E.Marx, “L' osteonecrosi dei mascellari da bifosfonati - Storia, Eziologia,Prevenzione e trattamento dell' osteonecrosi indotta dai bifosfonati per via orale e per viaendovenosa” Quintaessenza, Rho, Italia, 2009 (translated by S.Abati et al) .[127] L.Sottosanti “ Le segnalazioni all’AIFA. I dati della Rete Nazionale diFarmacovigilanza (RNF) sui Bifosfonati e ONJ “ in “Osteonecrosi dei mascellari (ONJ):Prevenzione, Diagnosi, Trattamento. Update 2009” available athttp://www.reteoncologica.it/images/stories/ONJ/Osteonecrosi_mascellari_2009/02-04%20Sottosanti%20Laura.pdf[128] EMEA “CHMP assessment report on bisphosphonates and osteonecrosis of the jaw”.London, 24 September 2009, available athttp://www.emea.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051428.pdf[129] L.Sottosanti “ Osteonecrosi della mandibola e farmaci biologici “ in “Reazioni.Bollettino di farmacovigilanza dell’AIFA” vol 14 (settembre 2009) pp 6-7 , available athttp://www.sefap.it/farmacovigilanza_news_200912/rea_14_2009.pdf[130] Additional safety information. In European Medicines Agency Monthly report (26November 2010), pag 2, available athttp://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2010/11/WC500099368.pdf22
Azienda Ospedaliera Nazionale“SS. Antonio e Biagio e Cesare Arrigo”Working Paper of Public Healthnr. 12/2012[131] AIFA. “Nota Informativa Importante su Avastin (bevacizumab) del 30/11/2010”availableathttp://www.agenziafarmaco.gov.it/sites/default/files/nota_informativa_importante_sullavastin_del_30-11-2010.pdf[132] AIFA. “Nota Informativa Importante su Sunitinib (Sutent) del 30/11/2010” available athttp://www.agenziafarmaco.gov.it/sites/default/files/nota_informativa_importante_su_sunitinib_30-11-10.pdf[133] Gruppo di Lavoro sull’Osteonecrosi da Bifosfonati della Rete Oncologica di Piemontee Valle d’Aosta “Newsletter n5 (Dicembre 2009)” , available athttp://www.reteoncologica.it/images/stories/scaffale/archivio/Gruppo_Osteonecrosi_Newsletter_5_2009.pdf[134] Osteonecrosi dei mascellari : “Slide gallery”, available athttp://www.reteoncologica.it/index.php?option=com_content&view=article&id=134&Itemid=85[135] Ministero del Lavoro, della Salute e delle Politiche Sociali “Raccomandazione per laprevenzione dell’osteonecrosi della mascella / mandibola da bifosfonati“ Raccomandazionen.10, settembre 2009 , available athttp://www.salute.gov.it/imgs/C_17_pubblicazioni_1077_allegato.pdf[136] V. Fusco, C. Ortega, F. Goia, L. Ciuffreda, M. Ardine, P. Falco, G. Gorzeglio, A.Baraldi, M. Airoldi, O. Bertetto “Bisphosphonates (BP)-related Osteonecrosis of the Jaw(ONJ): clinical experience of the “Rete Oncologica di Piemonte e Valle d’Aosta” network.”Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No.18S (June 20 Supplement): 18584, 2006[137] N. D’Alessandro, I. Morreale “Esperienza della Regione Sicilia” in in “Osteonecrosidei mascellari (ONJ): Prevenzione, Diagnosi, Trattamento. Update 2009” , available athttp://www.reteoncologica.it/images/stories/slideOnline/osteonecrosi/morreale%20-%20dalessandro.pdf[138] BE Hillner, JN Ingle, JR Berenson, et al: American Society of Clinical OncologyGuideline on the Role of Bisphosphonates in Breast Cancer. J Clin Oncol 18:1378-1391,2000[139] BE Hillner, JN Ingle, RT Chlebowski, et al: American Society of Clinical Oncology2003 update on the role of bisphosphonates and bone health issues in women with breastcancer. J Clin Oncol 21:4042-4057, 200323
Page 2 and 3:
La serie di Working Paper of Public
Page 4 and 5:
Azienda Ospedaliera Nazionale“SS.
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Azienda Ospedaliera NazionaleSS. An
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91: Azienda Ospedaliera Nazionale“SS.
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
show all

Working Paper of Public Health Volume 2012 - Azienda Ospedaliera ...

Create successful ePaper yourself

Delete template?

Save as template?